跳到正文

AMGEN INC

AMGN · XNAS

CIK 318154fmd_02T53VP4T86EN7A5VXW3G0PZWN制造业 · 生物制品(不含诊断试剂)模板: 标准

覆盖范围: 2007年1月01日 至 2026年9月30日,共 75 个期间

利润表 · 年度 · 百万 · USD
项目FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
营业总收入22,99122,84923,74723,36225,42425,97926,32328,19033,42436,751
营业成本4,1624,0694,1014,3566,1596,4546,4068,45112,85812,037
毛利润18,82918,78019,64619,00619,26519,52519,91719,73920,56624,714
研发费用3,8403,5623,7374,1164,2074,8194,4344,7845,9647,272
销售、一般及管理费用5,0624,8705,3325,1505,7305,3685,4146,1797,0967,050
营业利润9,7949,97310,2639,6749,1397,6399,5667,8977,2589,080
利息费用1,2601,3041,3921,2891,2621,1971,4062,8753,1552,755
利息及投资收益–––––111271,200510408
其他营业外收入(支出)629928674753256259(814)2,8335062,651
税前利润9,1639,5979,5459,1388,1336,7017,3467,8554,6098,976
所得税费用1,4417,6181,1511,2968698087941,1385191,265
持续经营净利润7,7221,9798,3947,8427,2645,8936,5526,7174,0907,711
净利润7,7221,9798,3947,8427,2645,8936,5526,7174,0907,711